Please provide your email address to receive an email when new articles are posted on . The FDA has approved Linzess, the first therapy for pediatric functional constipation in patients aged 6 to 17 ...
FDA has announced it has approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation in adults, according to a news release. Linzess ...
The US Food and Drug Administration has expanded its approval of Ironwood Pharmaceuticals' (NASDAQ:IRWD) drug Linzess to include the treatment of functional constipation in children and teens. Linzess ...
Please provide your email address to receive an email when new articles are posted on . AbbVie announced that it has submitted a supplemental new drug application for Linzess for the treatment of ...
The FDA has approved linaclotide (Linzess) for children aged 7 years or older with irritable bowel syndrome with constipation (IBS-C), making it the first approved treatment for pediatric IBS-C. The ...
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a leading global gastrointestinal healthcare company, will present findings during the 2023 North American Society for Pediatric ...
The FDA approved an oral suspension product that combines omeprazole and sodium bicarbonate (Konvomep) to treat benign active gastric ulcers and reduce the risk of upper gastrointestinal bleeds in ...
Zacks Investment Research on MSN
Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3?
Ironwood Pharmaceuticals’ IRWD sole marketed product, Linzess (linaclotide), has witnessed a strong uptake in recent quarters. The company markets Linzess in the United States in collaboration with ...
– Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million – – LINZESS (Iinaclotide) EUTRx prescription demand growth in Q1 2025 of 8% ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback